Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Guymer, Robyn H ^a   Baird, Paul N ^a   Varsamidis, Mary ^a   Busija, Lucy ^a,b   Dimitrov, Peter N ^a   Aung, Khin Zaw ^a   Makeyeva, Galina A ^a   Richardson, Andrea J ^a   Lim, Lyndell ^a   Robman, Liubov D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E2; COMPLEMENT FACTOR H; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERVENTION STUDIES; MACULAR DEGENERATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SIMVASTATIN;

EID: 84894283540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083759     Document Type: Article

References (45)

1. Zhou Q, Liao JK (2010) Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J 74: 818-826.
2. Guymer RH, Chiu AW, Lim L, Baird PN (2005) HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? Surve Ohthalmol 50: 194-206. (Pubitemid 40340950)
3. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN (2001) Risk of macular degeneration in users of statins: cross sectional study. BMJ 323: 375-376. (Pubitemid 32762463)
4. McCarty CA, Mukesh BN, Guymer RH, Baird PN, Taylor HR (2001) Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. MJA 175: 17.
5. McGwin Jr G, Owsley C, Curcio CA, Crain RJ (2003) The association between statin use and age related maculopathy. BJO 87:1121-1125. (Pubitemid 37064888)
6. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL (2004) Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 137: 615-624. (Pubitemid 38446673)
7. Tan JS, Mitchell P, Rochtchina E, Wang JJ (2007) Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. Am J Ophthalmol 143: 685-687. (Pubitemid 46452504)
8. Chuo JY, Wiens M, Etminan M, Maberley DA (2007) Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies. Ophthalmic Epidemiol 14: 367-374.
9. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE (2005) A case control study of age related macular degeneration and use of statins. BJO 89: 1171-1175. (Pubitemid 41224469)
10. Klein R, Knudtson MD, Klein BE (2007) Statin Use and the Five-Year Incidence and Progression of Age-related Macular Degeneration. Am J Ophthalmol 144: 1-6.
11. van Leeuwen R, Tomany SC, Wang JJ, Klein R, Mitchell P, et al. (2004) Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology 111: 1169-1175. (Pubitemid 38736996)
12. Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, et al. (2001) Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 8: 237-249. (Pubitemid 32681944)
13. Maguire MG, Ying GS, McCannel CA, Liu CC, Dai Y, et al. (2009) Statin Use and the Incidence of Advanced Age-related Macular Degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology 116: 2381-2385.
14. Fong DS, Contreras R (2010) Recent statin use and 1-year incidence of exudative age-related macular degeneration. Am J Ophthalmol 149: 955-958.
15. Shalev V, Sror M, Goldshtein I, Kokia E, Chodick G (2011) Statin Use and the Risk of Age Related Macular Degeneration in a Large Health Organization in Israel. Ophthalmic Epidemiol 18: 83-90.
16. Martini E, Scorolli L, Burgagni M, Fessehaie S (1991) Valutazione degli effetti retinici della somministrazione di simvastatina in pazienti affetti da degenerazione maculare senile. Annali Di Ottalmologia e Clinica Oculistica 117: 1121-1126.
17. VanderBeek BL, Zacks DN, Talwar N, Nan B, Stein JD (2013) Role of statins in the development and progression of age-related macular degeneration. Retina 33: 414-422.
18. Gehlbach P, Li T, Hatef E (2009) Statins for age-related macular degeneration. Cochrane Database of Systematic Reviews.
19. Tsao SW, Fong DS (2013) Do statins have a role in the prevention of age-related macular degeneration? Drugs Aging 30: 205-213.
20. Guymer RH, Dimitrov PN, Varsamidis M, Lim LL, Baird PN, et al. (2008) Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS). Clin Interv Aging 3: 581-593.
21. rd FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, et al. (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120: 844-851.
22. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587. (Pubitemid 28182422)
23. National Heart Foundation of Australia (2001) Cardiac Society of Australia and New Zealand. MJA 175(Suppl): S57-S85.
24. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367-374.
25. Aung KZ, Robman L, Chong EW, English DR, Giles GG, et al. (2009) Non-mydriatic digital macular photography: how good is the second eye photograph? Ophthalmic Epidemiol 16: 254-261.
26. Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ (2002) Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 325: 11-17.
27. Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH (2010) C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 117: 1982-1988.
28. van Leeuwen R, Chakravarthy U, Vingerling JR, Brussee C, Hooghart AJ, et al. (2003) Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? Ophthalmology 110: 1540-1544. (Pubitemid 36962486)
29. Seipp MT, Durtschi JD, Voelkerding KV, Wittwer CT (2009) Multiplex amplicon genotyping by high-resolution melting. J Biomol Tech 20: 160-164.
30. Baird PN, Islam FM, Richardson AJ, Cain M, Hunt N, et al. (2006) Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. Invest Ophthalmol Vis Sci 47: 4194-4198. (Pubitemid 46591223)
31. Baird PN, Guida E, Chu DT, Vu HT, Guymer RH (2004) The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 45: 1311-1315. (Pubitemid 38859305)
32. Baird P, Richardson A, Robman L, Dimitrov P, Tikellis G, et al. (2006) Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat 27(4): 337-42.
33. Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 119: 1417-1436.
34. Age-Related Eye Disease Study 2 Research Group (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309: 2005-2015.
35. Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, et al. (2005) A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 123: 1570-1574. (Pubitemid 41626694)
36. Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, et al. (2005) The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 123: 1484-1498. (Pubitemid 41626684)
37. Dupont WD, Plummer Jr DP (2009) PS - Power and Sample Size Calculation Version 3.0.12 Accessed December 18, 2009. http://biostat.mc.vanderbilt.edu/ wiki/Main/PowerSampleSize.
38. Adams MK, Simpson JA, Richardson AJ, English DR, Aung KZ, et al. (2012) Apolipoprotein E Gene Associations in Age-related Macular Degeneration: The Melbourne Collaborative Cohort Study. Am J Epidemiol 175: 511-518.
39. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, et al. (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 77: 3957-3961. (Pubitemid 10015499)
40. Alberts AW (1988) Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62: 10J-15J.
41. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
42. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-1182.
43. Australian Government (2008) Most commonly used drugs in the Australian community for 2008. Australian Statistics on Medicines.
44. Mant A, Lowinger J, Hall W, Whicker S, Ringland C, et al. (2007) Statins down under. Br J Clin Pharmacol 63: 125-127.
45. Klein R, Knudtson MD, Lee KE, Gangnon RE, Klein BE (2008) Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 115: 1460-1467.